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KEY INSIGHTS 
1. In general, cancer patients are becoming increasingly 
aware of different aspects related to their treatment. 
They are demanding information transparency and are 
more than willing to be involved in their treatment 
journey.  
2. Technology is the core to most of the value added 
service (VAS) models currently available in market. 
  
3. The key focus for any immuno-oncology service 
model should be the patient health monitoring between 
two infusion (drug administration) appointments. 
 
4. It is imperative to collaborate with other stakeholders 
like physicians, pharmacists, and healthcare providers 
etc. to deliver VAS more effectively. A robust value 
proposition must be defined to incentivize them to 
collaborate with the bio-pharmaceutical company. 
 
Introduction 
The emerging long-term picture of bio-pharmaceutical 
industry is exciting, with many disruptive innovations. 
However on a long term, a biopharmaceutical company has 
to maintain competitiveness by ensuring affordability, 
quality, and delivery performance. [Mckinsey Report: Otto 
et al. 2014].   
 
Within this scenario, a bio-pharmaceutical global leader 
(BPC) is trying to understand the unmet patient needs in 
immuno-oncology space and how they can devise a service 
strategy to meet those needs with compliance. This thesis is 
a humble attempt to close this gap and help the industry 
evolve with innovative service offerings. The scope of the 
project is limited to immuno-oncology space in France, 
which is a key market for the sponsoring company. 
If a robust service strategy can be devised and implemented, 
it will not only give a competitive advantage to the 
sponsoring company, but will drive the industry forward 
towards the ultimate goal of making life easier for patients. 
Methodology 
We started with thorough literature review, which was done 
to understand the current VAS landscape in 
biopharmaceutical industry. Apart from this, a competitive 
benchmarking was performed with 11 close competitors. In 
the best interest of the thesis, we did not limit our 
competitors to only immuno-oncology area as we realized 
that we may come across many nice examples of VAS from 
other therapeutic areas as well. 
 
Later, we conducted face to face and telephonic interviews 
with many healthcare professionals from France and Spain, 
over a period of 3 months. We had 12 such interviews in 
Barcelona and 6 in Paris. Apart from this, telephonic 
interviews were also conducted with professionals in 
Barcelona and Madrid, whenever it was deemed necessary. 
 
Summary: 
Over the past decade, the biopharmaceutical industry has experienced substantial growth and this trend is expected to continue.  
As every major player is looking for ways to surge ahead of competition, providing value added services to patients is one way 
to gain competitive advantage. 
 
This thesis aims to identify the kind of services patients would like to see coming their way. The authors used both primary 
and secondary research techniques to identify the unmet patient needs and subsequently developed two service models to 
deliver these services in an effective manner. 
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 Figure 1: The current process map and potential scope for 
value added services, Source: own 
Also, separate questionnaires were designed for prescribers 
and hospital pharmacists in France. Although we could not 
complete the survey in time due to legal complications, the 
questionnaires have been included as a part of the thesis for 
future reference.   
Models developed 
Based on both primary and secondary research, we 
developed the service models for the two intended service 
channels (Direct to patient via IT model, collaboration 
model with healthcare providers).  
Model 1- Direct to patient via IT Model (Mobile APP) 
Our proposed APP platform is a comprehensive service 
bundle, which is currently not available in the market. 
 
Figure 2: A sketch illustrating the proposed flow of 
information for our mobile APP 
 
As shown in Figure 2, the idea is to link the de-identified 
portion of the data, retrieved from the Hospital ERP to the 
mobile APP. Critical data elements like adherence data, side 
effects data etc. can flow both to backend database 
administrators as well as Hospital ERP. A healthcare coach 
or hospital pharmacist can make use of this data to help the 
patients in their journey. This unique model, if applied on 
the principles of data security, forms the backbone of our 
value added service (VAS) offerings. The six VAS offering 
for which we have developed functional specifications are 
“Treatment adherence”, “Appointments support”, “Possible 
Drug interaction”, “Side effects Management”, “Patient 
education and management” and “Oncology updates”. We 
also performed a NPV analysis for this investment, taking 
in to account the additional revenue due to expected 
increase in adherence.  
Model 2- Collaboration with healthcare providers 
When a patient, visiting a hospital, is prescribed immuno-
oncology product, he/she is automatically entitled to all the 
services offered by the proposed “Integrated Care Centres”. 
The Hospital is expected to provide the necessary 
infrastructure to carry out the operations. BPC is expected 
to take care of all expenses related to the salaries of full time 
oncologists, pharmacists, nurses, administrative staffs and 
psychologists etc., necessary to offer the intended services.   
 
 
  
Figure 3: A sketch illustrating the proposed “Integrated 
Care Centres” within the Hospital infrastructure 
 
The VAS offerings that can be provided by these centers are 
“On Call support”, “Home care infusion”, “Workshops 
around Patient education and Lifestyle management” etc. 
 
Our model is a win-win situation for all the key stakeholders 
(i.e, the patients, the hospital as well as BPC) as we have 
strong value proposition for all the parties involved.  
Conclusion 
We found that the amount of financial risk the company 
would subject itself with Model 1 investment is negligible. 
However the legal, regulatory, IT-security and brand image 
risks are significant and need to be factored. In Model 2, a 
strong value proposition exists for hospitals but convincing 
the key opinion leaders and overcoming the regulatory 
barriers are again the biggest challenges. However a pilot 
run can be carried out in Paris and then a decision can be 
taken if the model is scalable. Overall both the models are 
innovative and first of its kind for bio-pharmaceutical 
industry. 
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